Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study

NCT: NCT06604884 · RECRUITING

NCT IDNCT06604884
StatusRECRUITING
Start Date2025-12-12
Completion2033-09

Brief Summary

The purpose of the Pipeline™ Vantage Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Vantage PAS") is to collect safety and effectiveness data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Vantage Embolization Device with Shield Technology™ ("Pipeline™ Vantage Device") in a post approval setting.

Frequently Asked Questions

What is NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study?

NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study is a clinical trial registered under NCT06604884. Current status: RECRUITING.

What is the status of NCT06604884?

The current status of NCT06604884 (NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study) is: RECRUITING.

When did NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study start?

NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study started on 2025-12-12.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑